Ramat Gan, Israel

Edna Bechor

This inventor holds 2 USPTO granted patents and 2 EPO patents. Top assignee: Omrix Biopharmaceuticals Inc.. Active years: 2015-2016.


 

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2015-2016

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Edna Bechor: Innovator in Spinal Disease Treatment

Introduction

Edna Bechor is a prominent inventor based in Ramat Gan, Israel. She has made significant contributions to the field of biopharmaceuticals, particularly in the treatment of spinal diseases. With a total of 2 patents, her work focuses on innovative solutions that address critical health issues.

Latest Patents

Edna Bechor's latest patents include compositions suitable for the treatment of spinal diseases, disorders, or conditions. One of her notable inventions relates to the use of viral inactivated-plasma cryoprecipitate concentrate (VIPCC) that comprises a suitable fibronectin/fibrinogen ratio. This invention aims to treat conditions such as intervertebral disc degeneration, showcasing her commitment to advancing medical treatments.

Career Highlights

Throughout her career, Edna has been associated with Omrix Biopharmaceuticals Inc., where she has played a vital role in research and development. Her expertise in biopharmaceuticals has positioned her as a key figure in the industry, contributing to innovative therapies that improve patient outcomes.

Collaborations

Edna has collaborated with several professionals in her field, including Liliana Bar and Israel Nur. These partnerships have enhanced her research efforts and expanded the impact of her inventions.

Conclusion

Edna Bechor's contributions to the treatment of spinal diseases through her innovative patents highlight her dedication to improving healthcare. Her work continues to inspire advancements in biopharmaceuticals, making a significant difference in the lives of patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…